Explore Citius Oncology's Q4 2024 financial performance, including a $6.6M net loss, cash struggles, and reliance on parent funding, all crucial for investor decisions.
Explore Citius Oncology, Inc.'s 8-K report filed on February 14, 2025, revealing key financial updates, corporate details, and stock information for investors.
Discover critical insights from Citius Oncology's Form 8-K report dated January 7, 2025, covering significant corporate events and financial updates. Stay informed on CTOR!
Explore Citius Oncology's 8-K filing detailing significant events, financial metrics, and stock performance as of January 6, 2025. Essential for investors and analysts.
Explore Citius Oncology's Q4 2024 financial analysis, highlighting a $21.15M net loss, $112 cash, and crucial R&D commitments. Investors advised to hold amidst uncertainties.
Explore Citius Oncology's significant 8-K report filed on December 27, 2024, revealing critical updates on corporate events and stock performance. NASDAQ: CTOR.